Drug Discovery

BeiGene acquires rights to Zymeworks’ ZW25 and ZW49 bispecific candidates in Asia-Pacific

Zymeworks and BeiGene have entered into a collaboration for the clinical development and commercialization of the former’s investigational ZW25 and ZW49 HER2-targeted bispecific antibodies.

Roche’s Genentech agrees to buy Jecure Therapeutics

Roche Group’s member Genentech has agreed to acquire US-based biotechnology firm, Jecure Therapeutics, for an undisclosed sum.

Cyclica, Bayer partner to advance drug discovery programs

Cyclica has partnered with Bayer to drives drug discovery through artificial intelligence (AI)-augmented integrated network of cloud-based technologies.

Vineti, Tessa partner to advance cancer immunotherapies

Vineti has entered into a new partnership with Tessa Therapeutics to advance and scale personalized cell therapies for solid tumors in Asia and world-wide.

Evotec, Immuneering partner on AI-driven approach to ligand identification

Evotec has entered into a research collaboration with Immuneering on artificial intelligence (AI) driven ligand identification for rare hereditary metabolic diseases.

LEO Pharma, PellePharm form $760m rare skin disease collaboration

LEO Pharma and PellePharm have entered into a development and commercialization collaboration to address unmet medical needs in various skin diseases like Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC).

Boehringer, Epizyme announce $300m oncology therapy program

Boehringer Ingelheim has entered into a new global collaboration with Epizyme to develop novel epigenetic oncology therapies.

Scientists engineer DNA-encoded monoclonal antibodies targeting Zaire Ebolavirus

Scientists at The Wistar Institute and collaborators have engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models.

Biopharmaceutical firm NextCure completes $93m series B equity financing

NextCure, a biopharmaceutical firm engaged in the discovery and development of next generation immunomedicines for cancer and other diseases, has raised $93m in Series B financing.